Ovid Therapeutics (OVID) vs. Its Competitors Financial Comparison

Ovid Therapeutics (NASDAQ: OVID) is one of 289 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Ovid Therapeutics to related companies based on the strength of its institutional ownership, valuation, analyst recommendations, earnings, profitability, dividends and risk.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Ovid Therapeutics and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ovid Therapeutics 0 0 4 0 3.00
Ovid Therapeutics Competitors 1134 3426 11925 240 2.67

Ovid Therapeutics presently has a consensus price target of $23.50, indicating a potential upside of 146.85%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.53%. Given Ovid Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Ovid Therapeutics is more favorable than its peers.

Earnings & Valuation

This table compares Ovid Therapeutics and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Ovid Therapeutics N/A -$22.41 million N/A
Ovid Therapeutics Competitors $290.27 million $35.99 million 55.49

Ovid Therapeutics’ peers have higher revenue and earnings than Ovid Therapeutics.


This table compares Ovid Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ovid Therapeutics N/A -86.05% -80.34%
Ovid Therapeutics Competitors -5,443.85% -164.39% -36.43%

Institutional & Insider Ownership

29.4% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 49.6% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 17.4% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.


Ovid Therapeutics peers beat Ovid Therapeutics on 6 of the 11 factors compared.

About Ovid Therapeutics

Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.

What are top analysts saying about Ovid Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ovid Therapeutics and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit